MW Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
By Steve Goldstein
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram once-per-week dose taken for 36 weeks.
This trial was done by injecting patients - which is how popular drugs Ozempic and Wegovy are administered - but it's also being developed for oral administration.
It said most of the side effects were gastrointestinal and mild to moderate in severity.
Novo Nordisk said it is now planning further clinical development of amycretin in adults with overweight or obesity.
Novo Nordisk stock (DK:NOVO.B) $(NVO)$ rallied 12% in Copenhagen trade, though it's still down about 13% from where it was after a disappointing trial of CagriSema.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
January 24, 2025 08:47 ET (13:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.